Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): October 14, 2009
 
 
ZIOPHARM Oncology, Inc.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
  
0-32353
  
84-1475672
(State or Other Jurisdiction
of Incorporation)
  
(Commission File Number)
  
(IRS Employer
Identification No.)
 
1180 Avenue of the Americas
19th Floor
New York, NY
  
10036
(Address of Principal Executive Offices)
  
(Zip Code)
 
(646) 214-0700
(Registrant’s telephone number, including area code)
 
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
 
 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
 
o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
 
 
 
 
 
Item 8.01
  
Other Events

On October 14, 2009, the Company issued a press release announcing interim analysis data from its randomized phase II trial of palifosfamide (ZymafosTM, ZIO-201) in treating patients with unresectable or metastatic soft tissue sarcoma.

A copy of the above referenced press release is filed as Exhibit  99.1 to this Current Report of Form 8-K.

 
 
Financial Statements and Exhibits
         
    (d)
  
Exhibits
    
         
   
Exhibit No.
  
Description
         
   
99.1
  
Press Release of the Company dated October 14, 2009

 
2
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
ZIOPHARM Oncology, Inc.
  
     
       
 
By:
/s/ Richard Bagley
  
Date: October 14, 2009
  
Name: Richard Bagley
  
   
Title: President, Chief Operating Officer and Chief Financial Officer
       
 
 
3
 
 
INDEX OF EXHIBITS
 
Exhibit No.
  
Description
     
99.1
  
Press Release of the Company dated October 14, 2009
 
 
4